Braidwell LP Buys Shares of 34,094 Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Braidwell LP purchased a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 34,094 shares of the company’s stock, valued at approximately $654,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC increased its holdings in Viridian Therapeutics by 113.1% during the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock valued at $2,851,000 after acquiring an additional 66,550 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Viridian Therapeutics by 218.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock worth $9,108,000 after purchasing an additional 274,641 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of Viridian Therapeutics by 6.8% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 210,899 shares of the company’s stock worth $4,043,000 after purchasing an additional 13,498 shares during the last quarter. SG Americas Securities LLC lifted its stake in Viridian Therapeutics by 89.1% in the 4th quarter. SG Americas Securities LLC now owns 31,085 shares of the company’s stock valued at $596,000 after buying an additional 14,644 shares in the last quarter. Finally, Moody Aldrich Partners LLC acquired a new stake in Viridian Therapeutics during the 4th quarter valued at $1,125,000.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Price Performance

Viridian Therapeutics stock opened at $13.12 on Tuesday. Viridian Therapeutics, Inc. has a 1 year low of $9.90 and a 1 year high of $27.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The firm has a 50 day moving average price of $13.92 and a 200 day moving average price of $17.77. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -3.04 and a beta of 0.57.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.24. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.